In this investigation, we evaluated the clinical outcomes specifically in patients with acute coronary syndrome (ACS) who, according to the study protocol, between 31 and 365 days after randomization were to receive either ticagrelor alone or ticagrelor and aspirin (ASA) at a dose of 75 mg to 100 mg daily. CAD indicates coronary artery disease; NSTEMI, non–ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction; UA, unstable angina.